ICH Care Bundles & Neurointensive Care

The management of intracerebral hemorrhage (ICH) extends well beyond blood pressure and surgery. INTERACT3 (2023) demonstrated that a protocolized care bundle — integrating BP control, glucose management, temperature control, and anticoagulation reversal — produced the first positive phase 3 result in acute ICH. This "bundle approach" reflects a growing understanding that multiple concurrent interventions, rather than single-target therapies, optimize ICH outcomes. Beyond the acute bundle, neurointensive care encompasses seizure management, ICP control, cerebral edema treatment, VTE prophylaxis, prognostication, and early rehabilitation — each with specific guideline recommendations and pitfalls.

1. The Care Bundle: INTERACT3

INTERACT3 (2023) was a landmark stepped-wedge cluster RCT across 121 hospitals in 10 countries (7,036 patients) that tested a goal-directed care bundle for acute ICH. The bundle comprised four simultaneous targets:

Key Results

• Primary endpoint (ordinal mRS at 6 months): Significant improvement with bundle (OR 0.86; 95% CI 0.76–0.97; p=0.015)
• Mortality: Reduced by 3% absolute (13.6% vs. 16.6%; OR 0.77; 95% CI 0.63–0.94; p=0.015; NNT ~35)
• Serious adverse events: Fewer in the bundle group
• Practical impact: This was the first positive phase 3 RCT in acute ICH — a watershed moment for the field

The significance of INTERACT3 lies not just in its positive result, but in demonstrating that systems-level protocolized care can overcome the individual limitations of each component therapy. No single intervention in the bundle had previously shown definitive benefit on its own — the synergy of multiple targets, implemented reliably and rapidly, drove the outcome.

2. Seizure Management

Seizures occur in approximately 8–16% of ICH patients, with clinical seizures most common within the first 24–72 hours. Subclinical electrographic seizures are more frequent (up to 28% on continuous EEG monitoring) and are independently associated with worse outcomes. However, the management approach is nuanced — treating confirmed seizures is essential, while prophylactic treatment is not beneficial.

Risk factors for post-ICH seizures include cortical involvement (lobar ICH), large hematoma volume, and younger age. Lobar hemorrhages carry the highest seizure risk (~15–20%), while purely deep ICH has a lower incidence (~5–8%). For patients who develop seizures, levetiracetam is typically preferred due to its favorable side-effect profile and IV availability, though no specific ASD is recommended by guidelines.

3. ICP Management & Cerebral Edema

Elevated intracranial pressure (ICP) in ICH results from both the mass effect of the hematoma and surrounding perihematomal edema (PHE). PHE peaks at approximately 10–14 days and independently predicts poor outcome — for every 1 mL increase in PHE, the risk of poor functional outcome rises by approximately 3%.

3.1 EVD & ICP Monitoring

• EVD for hydrocephalus: Class 1 recommendation. Indicated for IVH-related obstructive hydrocephalus or hydrocephalus with clinical deterioration.
• ICP monitoring: Reasonable in patients with GCS ≤8, clinical signs of herniation, or significant IVH/hydrocephalus (Class 2b).
• ICP target: Generally maintain cerebral perfusion pressure (CPP) 50–70 mmHg and ICP <22 mmHg, though specific ICH-targeted thresholds are not established.

3.2 Medical ICP Management

• Hyperosmolar therapy (mannitol, hypertonic saline): May be useful for acute ICP crises (Class 2b), but no RCT evidence supports routine use in ICH.
• Head of bed elevation: 30° is standard practice, though evidence is limited.
• Sedation and analgesia: Adequate pain control reduces ICP spikes; propofol or midazolam for intubated patients.

4. General Neurointensive Care

4.1 Glucose Management

Both hyperglycemia and hypoglycemia are associated with worse outcomes in ICH. The INTERACT3 bundle targets glucose 6.1–7.8 mmol/L in non-diabetics and 7.8–10.0 mmol/L in diabetics. Insulin infusions should be protocolized with frequent monitoring (Q1–2h during active titration). Intensive insulin therapy targeting normoglycemia (<6.1 mmol/L) is NOT recommended due to hypoglycemia risk.

4.2 Temperature Management

Fever (>37.5°C) occurs in up to 40% of ICH patients and is independently associated with larger HE, greater edema, and worse outcomes. The INTERACT3 bundle uses a temperature threshold of ≤37.5°C with scheduled acetaminophen and active cooling as needed. While antipyrexia as a stand-alone intervention has not been proven beneficial (2025 ESO: weak recommendation against stand-alone temperature management), it is a valuable component within the bundle approach.

4.3 VTE Prophylaxis

ICH patients are at high VTE risk due to immobility, often compounded by obesity and critical illness. Management involves balancing VTE prevention against re-bleeding risk:

• Mechanical prophylaxis: Intermittent pneumatic compression (IPC) from admission (Class 1).
• Pharmacologic prophylaxis: Low-dose subcutaneous heparin or LMWH may be considered after 24–48 hours if the hematoma is stable on repeat imaging and no coagulopathy exists (Class 2b). Earlier initiation (<24h) is not recommended.
• Graduated compression stockings alone: Not effective for VTE prevention (Class 3: No Benefit, based on CLOTS trial data).

4.4 Dysphagia & Nutrition

Aspiration pneumonia is a leading cause of post-ICH mortality. Formal swallow assessment should be performed before oral intake in all ICH patients (Class 1). For patients who cannot safely swallow, early enteral nutrition (within 72 hours) via nasogastric tube is preferred over parenteral nutrition.

5. Prognostication & Goals of Care

Prognostication in ICH is fraught with pitfalls. The ICH Score, while widely used, has significant limitations, and premature withdrawal of aggressive treatment — the "self-fulfilling prophecy" — remains the most important modifiable barrier to improved ICH outcomes.

Predictors of better outcome despite severe initial presentation include younger age, predominantly lobar location (potentially surgical candidates), absence of IVH, and favorable premorbid status. Biomarkers and advanced imaging (MRI, PET) may eventually improve early prognostication, but are not yet validated for clinical decision-making.

6. Rehabilitation

Rehabilitation after ICH follows the same principles as ischemic stroke recovery, with some important caveats. Early mobilization timing and intensity require careful consideration.

6.1 Early Mobilization: Lessons from AVERT

AVERT (2015) was a pivotal trial that enrolled 2,104 stroke patients (including ICH) and found that very early (<24 hours) and intensive mobilization was associated with worse functional outcomes at 3 months (adjusted OR 0.73; 95% CI 0.59–0.90). The harm was most pronounced in patients with ICH and severe stroke.

• Class 3: Harm: Very early, intensive mobilization (high frequency and out-of-bed activity within 24 hours) is not recommended.
• Moderate mobilization after 24–48 hours of stability is reasonable, with gradual progression based on clinical status.

6.2 Multidisciplinary Rehabilitation

Post-ICH depression is common (up to 25–50%) and significantly impairs rehabilitation outcomes and quality of life. Routine screening and early treatment with SSRIs are recommended. However, fluoxetine specifically for motor recovery — despite initial enthusiasm from the FLAME trial — was definitively shown to be ineffective by the FOCUS and AFFINITY trials.

7. Neurobehavioral Outcomes

ICH survivors face significant neurobehavioral challenges beyond motor deficits:

• Cognitive impairment: Present in 40–70% of survivors, affecting executive function, memory, and attention. More common with IVH, larger hematomas, and deep location.
• Fatigue: Reported by up to 50% of survivors and often the most debilitating long-term symptom.
• Apathy: Distinct from depression, common with deep/frontal ICH, and often under-recognized.
• Suicide risk: Elevated compared to the general population, warranting longitudinal screening.

Cognitive rehabilitation, occupational therapy, and speech-language pathology should be integral components of the multidisciplinary team. Pharmacologic treatment for post-ICH cognitive impairment has limited evidence — cholinesterase inhibitors are not routinely recommended.

8. Guideline Summary: General ICH Care

9. Trial Comparison Table

References

1. Ma L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3). Lancet. 2023;402(10395):27–40.
2. AVERT Trial Collaboration Group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT). Lancet. 2015;386(9988):46–55.
3. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS). Lancet. 2019;393(10168):265–274.
4. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY). Lancet Neurol. 2020;19(8):651–660.
5. Greenberg SM, et al. 2022 Guideline for the Management of Patients With Spontaneous ICH. Stroke. 2022;53(7):e282–e361.
6. Steiner T, et al. European Stroke Organisation (ESO) guideline on stroke due to spontaneous intracerebral haemorrhage. Eur Stroke J. 2025.